<DOC>
	<DOC>NCT01137435</DOC>
	<brief_summary>This safety surveillance study is being conducted in accordance with Korea Food and Drug Administration (KFDA) Notification No. 2009-46 "Basic standard for reexamination of new drug". The study objective is to assess within 30 days post-administration, the safety of ADACEL™ administered under the real clinical practice.</brief_summary>
	<brief_title>Post Marketing Surveillance for ADACEL™ in South Korea</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Inclusion Criteria : Subjects who are 11 through 64 years of age (as indicated in the currently approved local product labeling) , who are given a single dose of the study vaccine, during a routine healthcare visit, as active booster immunization for the prevention of tetanus, diphtheria and pertussis. Written informed consent obtained from the subject. For subjects below the legal age of consent, written informed consent must be obtained from the parent or legal guardian (legally acceptable representative LAR) of the subject. Exclusion Criteria :</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adacel</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
</DOC>